

# VOTE YES ON SB26-031

Concerning the lawful use of a prescription drug product containing a schedule I controlled substance

SPONSORED BY SENATOR DAFNA MICHAELSON JENET, SENATOR JANICE RICH, REPRESENTATIVE SEAN CAMACHO, AND REPRESENTATIVE MATT SOPER


## What this bill does

SB 26-031 exempts a prescription drug product that contains a schedule I controlled substance once the product is:

- Approved for prescription use by the United States Food and Drug Administration (FDA); and
- Rescheduled or otherwise designated for medical use by the United States Drug Enforcement Administration (DEA) following FDA approval.

The bill requires that, upon DEA rescheduling, the product be controlled in Colorado in the same manner as it is controlled under federal law.

## FDA Process



Colorado needs new innovative therapies for mental health.

## Why?

Mental health is a crisis we cannot ignore. Millions of Americans living with conditions such as generalized anxiety disorder, major depressive disorder, PTSD, and others do not experience adequate relief from existing treatments. With few new treatment options approved in recent decades, a significant unmet need remains.

New therapies are in development, and now is the time to invest in next-generation solutions so Colorado is ready to offer breakthrough treatments to patients once they are approved by the FDA and rescheduled by DEA.

## In Colorado



1 in 4 adults struggle with mental illness

**30%**

of adults report symptoms of anxiety or depression but not receiving counseling or therapy

**63%**

\*Colorado suicide rate is 22.8 vs 14 national per 100,000 deaths

Has a suicide rate of 22.8 suicides per 100,000 deaths (compared to the national average of 14 suicides per 100,000 deaths)

## Patient Access

There are vulnerable populations with chronic conditions, like veterans, who are actively looking for new and emerging medicines to help find relief from pain and disease.

## Government Efficiency

SB26-031 modernizes Colorado law by exempting prescription drugs containing the schedule I controlled substance when approved by FDA and rescheduled by DEA, streamlining patient access.